Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $59.99 USD
Change Today +1.05 / 1.78%
Volume 139.0K
LCI On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 9:48 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

lannett co inc (LCI) Snapshot

Open
$60.29
Previous Close
$58.94
Day High
$60.71
Day Low
$59.48
52 Week High
04/13/15 - $72.44
52 Week Low
05/8/14 - $32.01
Market Cap
2.1B
Average Volume 10 Days
916.4K
EPS TTM
$3.40
Shares Outstanding
35.8M
EX-Date
--
P/E TM
17.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for LANNETT CO INC (LCI)

Related News

No related news articles were found.

lannett co inc (LCI) Related Businessweek News

No Related Businessweek News Found

lannett co inc (LCI) Details

Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of branded pharmaceutical products in the United States. It offers solid oral, extended release, topical, and oral solution finished dosage forms of drugs that address a range of therapeutic areas. The company provides its products for various medical indications comprising glaucoma, migraine, antibiotic, pain management, anesthetic, endometriosis, anxiety, irritable bowel syndrome, obesity, congestive heart failure, antipsychotic, tuberculosis, thyroid deficiency, dryness of the mouth, epilepsy, gout, low sodium, bronchospasms, hypertension, and gallstone, as well as HIV. It also manufactures active pharmaceutical ingredients. Lannett Company, Inc. markets its products under the Diamox, Fioricet, Fiorinal, Fiorinal w/ Codeine #3, Cleocin, Danocrine, Valium, Bentyl, Tenuate, Dospan, Lanoxin, Adoxa, Periostat, Prolixin, Dilaudid, Niazid, Levoxyl, Synthroid, Loxitane, Adipex-P, Fastin, Salagen, Mysoline, Benemid, Rifadin, Brethine, Dyazide, Actigall, and Retrovir brands. The company sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. It has development and supply agreements with Azad Pharma AG, Swiss Caps of Switzerland, Pharma 2B, the GC Group of Israel, and HEC Pharm Group, as well as with Jerome Stevens Pharmaceuticals, Inc., Cerovene, and Summit Bioscience LLC. The company was founded in 1942 and is based in Philadelphia, Pennsylvania.

399 Employees
Last Reported Date: 08/29/14
Founded in 1942

lannett co inc (LCI) Top Compensated Officers

Chief Executive Officer, Director and Chairma...
Total Annual Compensation: $539.0K
Chief Financial Officer, Vice President of Fi...
Total Annual Compensation: $317.0K
Chief Operating Officer
Total Annual Compensation: $346.0K
Senior Vice President of Sales and Marketing
Total Annual Compensation: $278.0K
Compensation as of Fiscal Year 2014.

lannett co inc (LCI) Key Developments

Lannett Company, Inc. to Report Q3, 2015 Results on May 06, 2015

Lannett Company, Inc. announced that they will report Q3, 2015 results After-Market on May 06, 2015

Lannett Company, Inc., Q3 2015 Earnings Call, May 06, 2015

Lannett Company, Inc., Q3 2015 Earnings Call, May 06, 2015

Lannett Company, Inc. Expands Revolving Credit Facility to $120 Million

Lannett Company, Inc. announced that it has amended and increased its five-year revolving credit facility to $120 million from $50 million. The amended facility includes an accordion feature that will allow the company to increase borrowings by a total of up to an additional $30.0 million, subject to securing additional commitments from existing lenders or new lending institutions. The maturity date of the credit facility remains December 18, 2018. The amended credit facility, together with its strong balance sheet, provides financial firepower for Lannett's acquisition and organic growth strategy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LCI:US $59.99 USD +1.05

LCI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ANI Pharmaceuticals Inc $54.50 USD -1.10
Covisint Corp $1.90 USD +0.005
Impax Laboratories Inc $45.27 USD -0.265
Pernix Therapeutics Holdings Inc $6.47 USD +0.09
Sagent Pharmaceuticals Inc $23.22 USD -0.465
View Industry Companies
 

Industry Analysis

LCI

Industry Average

Valuation LCI Industry Range
Price/Earnings 17.7x
Price/Sales 5.9x
Price/Book 5.7x
Price/Cash Flow 17.2x
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LANNETT CO INC, please visit www.lannett.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.